Header Logo

Connection

VARSHA V GANDHI to Humans

Back to Details
This is a "connection" page, showing publications VARSHA V GANDHI has written about Humans.
VARSHA V GANDHI
Connection Strength
1.320
Humans
  1. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 09 10; 8(17):4487-4501.
    View in: PubMed
    Score: 0.019
  2. Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability. Oncotarget. 2023 06 21; 14:653-655.
    View in: PubMed
    Score: 0.017
  3. Curing CLL: one clone at a time. Blood Adv. 2023 05 09; 7(9):1926-1928.
    View in: PubMed
    Score: 0.017
  4. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clin Cancer Res. 2023 01 17; 29(2):446-457.
    View in: PubMed
    Score: 0.017
  5. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022 05 20; 12(5):80.
    View in: PubMed
    Score: 0.016
  6. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica. 2022 01 01; 107(1):292-297.
    View in: PubMed
    Score: 0.016
  7. Development and characterization of prototypes for in?vitro and in?vivo mouse models of ibrutinib-resistant CLL. Blood Adv. 2021 08 24; 5(16):3134-3146.
    View in: PubMed
    Score: 0.015
  8. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 2021 04 29; 11(4):79.
    View in: PubMed
    Score: 0.015
  9. The Right Dose: From Phase I to Clinical Practice. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:92-106.
    View in: PubMed
    Score: 0.015
  10. Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica. 2021 02 01; 106(2):495-512.
    View in: PubMed
    Score: 0.015
  11. Metabolism meets apoptosis in AML. Leuk Lymphoma. 2021 03; 62(3):514-516.
    View in: PubMed
    Score: 0.015
  12. Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies. Mol Cell Biochem. 2021 Jan; 476(1):417-423.
    View in: PubMed
    Score: 0.014
  13. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 07 15; 26(14):3856-3867.
    View in: PubMed
    Score: 0.014
  14. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2019 12; 60(12):3063-3066.
    View in: PubMed
    Score: 0.013
  15. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma. 2019 07; 60(7):1603-1605.
    View in: PubMed
    Score: 0.013
  16. Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia Cells. Methods Mol Biol. 2019; 1881:19-25.
    View in: PubMed
    Score: 0.013
  17. In Vitro Assay to Study CLL and Monocyte Interactions. Methods Mol Biol. 2019; 1881:113-119.
    View in: PubMed
    Score: 0.013
  18. Extracellular Flux Assays to Determine Oxidative Phosphorylation and Glycolysis in Chronic Lymphocytic Leukemia Cells. Methods Mol Biol. 2019; 1881:121-128.
    View in: PubMed
    Score: 0.013
  19. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259.
    View in: PubMed
    Score: 0.013
  20. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018 04; 32(4):920-930.
    View in: PubMed
    Score: 0.012
  21. Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma. 2018 06; 59(6):1427-1438.
    View in: PubMed
    Score: 0.012
  22. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia. 2017 Oct; 19(10):762-771.
    View in: PubMed
    Score: 0.012
  23. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res. 2017 12; 15(12):1692-1703.
    View in: PubMed
    Score: 0.012
  24. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol. 2017 10; 179(2):266-271.
    View in: PubMed
    Score: 0.012
  25. Duvelisib: a phosphoinositide-3 kinase d/? inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May; 26(5):625-632.
    View in: PubMed
    Score: 0.011
  26. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017 Mar 07; 8(10):16259-16274.
    View in: PubMed
    Score: 0.011
  27. A Conference of New Ideas in Cancer-Challenging Dogmas. Cancer Res. 2017 01 15; 77(2):234-237.
    View in: PubMed
    Score: 0.011
  28. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3734-3743.
    View in: PubMed
    Score: 0.011
  29. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia. 2017 09; 31(9):1872-1881.
    View in: PubMed
    Score: 0.011
  30. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol. 2017 Jan; 10(1):1-8.
    View in: PubMed
    Score: 0.011
  31. Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget. 2016 Jun 28; 7(26):39458-39472.
    View in: PubMed
    Score: 0.011
  32. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res. 2017 Jan 01; 23(1):181-192.
    View in: PubMed
    Score: 0.011
  33. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma. 2016 12; 57(12):2863-2873.
    View in: PubMed
    Score: 0.011
  34. Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clin Cancer Res. 2016 Sep 15; 22(18):4712-26.
    View in: PubMed
    Score: 0.011
  35. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):3461-76.
    View in: PubMed
    Score: 0.010
  36. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. Leuk Lymphoma. 2016; 57(6):1494-7.
    View in: PubMed
    Score: 0.010
  37. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells. Exp Hematol. 2015 Nov; 43(11):951-962.e3.
    View in: PubMed
    Score: 0.010
  38. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Sep; 29(9):1811-22.
    View in: PubMed
    Score: 0.010
  39. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3705-15.
    View in: PubMed
    Score: 0.010
  40. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015 Mar; 17(3):289-300.
    View in: PubMed
    Score: 0.010
  41. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood. 2015 Jan 08; 125(2):407-10.
    View in: PubMed
    Score: 0.010
  42. Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood. 2015 Feb 12; 125(7):1126-36.
    View in: PubMed
    Score: 0.010
  43. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46.
    View in: PubMed
    Score: 0.010
  44. Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL. Blood. 2014 Aug 14; 124(7):1192-5.
    View in: PubMed
    Score: 0.009
  45. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3780-9.
    View in: PubMed
    Score: 0.009
  46. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40.
    View in: PubMed
    Score: 0.009
  47. Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma. 2014 Sep; 55(9):1980-92.
    View in: PubMed
    Score: 0.009
  48. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments. Curr Pharm Des. 2014; 20(42):6670-81.
    View in: PubMed
    Score: 0.009
  49. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92.
    View in: PubMed
    Score: 0.009
  50. Uncoupling endoplasmic reticulum stress and autophagy: a potential implication for chronic lymphocytic leukemia therapy. Leuk Lymphoma. 2013 Dec; 54(12):2581-3.
    View in: PubMed
    Score: 0.009
  51. A new feature in Leukemia & Lymphoma: "Emerging drug profile". Leuk Lymphoma. 2013 Oct; 54(10):2131-2.
    View in: PubMed
    Score: 0.009
  52. Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Apr; 55(4):899-910.
    View in: PubMed
    Score: 0.009
  53. Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S355-62.
    View in: PubMed
    Score: 0.009
  54. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S317-29.
    View in: PubMed
    Score: 0.009
  55. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013 Oct; 31(5):1384-94.
    View in: PubMed
    Score: 0.009
  56. DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells. Leuk Lymphoma. 2014 Apr; 55(4):876-83.
    View in: PubMed
    Score: 0.009
  57. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):458-66.
    View in: PubMed
    Score: 0.009
  58. Meeting report: leaders in translational cancer research meet in Udaipur, a historical town of India: an International Symposium onTranslational Cancer Research: Cancer Prevention. Udaipur, Rajasthan, India, december 16-19, 2011. Anticancer Res. 2013 Apr; 33(4):1777-81.
    View in: PubMed
    Score: 0.009
  59. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood. 2012 Oct 25; 120(17):3491-500.
    View in: PubMed
    Score: 0.008
  60. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2013 May; 54(5):1097-100.
    View in: PubMed
    Score: 0.008
  61. ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage. Ther Deliv. 2012 Jul; 3(7):823-33.
    View in: PubMed
    Score: 0.008
  62. CCL2 in chronic lymphocytic leukemia: a macro in microenvironment? Leuk Lymphoma. 2012 Oct; 53(10):1849-50.
    View in: PubMed
    Score: 0.008
  63. Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma. 2012 Oct; 53(10):2024-32.
    View in: PubMed
    Score: 0.008
  64. Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2012 Apr; 21(4):409-23.
    View in: PubMed
    Score: 0.008
  65. Modifying the immune system to treat chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Feb; 53(2):177-8.
    View in: PubMed
    Score: 0.008
  66. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. J Pharmacol Exp Ther. 2011 Nov; 339(2):545-54.
    View in: PubMed
    Score: 0.008
  67. The micros in harmony: microRNA and microenvironment. Leuk Lymphoma. 2011 Sep; 52(9):1626-9.
    View in: PubMed
    Score: 0.008
  68. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 2011 Jul 21; 118(3):693-702.
    View in: PubMed
    Score: 0.008
  69. Yet another nucleoside analog for pancreatic cancer. Gastroenterology. 2011 Feb; 140(2):400-4.
    View in: PubMed
    Score: 0.007
  70. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood. 2010 Dec 16; 116(25):5622-30.
    View in: PubMed
    Score: 0.007
  71. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol. 2010 Dec 15; 80(12):1936-45.
    View in: PubMed
    Score: 0.007
  72. City of temples discusses signaling templates in cancer cells. Third International Symposium on Translational Cancer Research: Cell Signaling & Cancer Therapy. Bhubaneswar, Orissa, India, December 18th through 21st, 2009. Anticancer Res. 2010 Jun; 30(6):2477-80.
    View in: PubMed
    Score: 0.007
  73. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91.
    View in: PubMed
    Score: 0.007
  74. Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem. 2010 Mar 12; 285(11):8022-30.
    View in: PubMed
    Score: 0.007
  75. 8-Amino-adenosine inhibits multiple mechanisms of transcription. Mol Cancer Ther. 2010 Jan; 9(1):236-45.
    View in: PubMed
    Score: 0.007
  76. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood. 2009 Sep 17; 114(12):2560-1; author reply 2561-2.
    View in: PubMed
    Score: 0.007
  77. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009 Nov 05; 114(19):4150-7.
    View in: PubMed
    Score: 0.007
  78. Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol. 2009 Nov; 147(3):297-307.
    View in: PubMed
    Score: 0.007
  79. A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res Treat. 2010 Jun; 121(2):355-64.
    View in: PubMed
    Score: 0.007
  80. Myeloma antioxidant status: the good, the bad and the reactive. Leuk Lymphoma. 2009 May; 50(5):691-3.
    View in: PubMed
    Score: 0.007
  81. Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d. Cancer Res. 2009 May 01; 69(9):3947-54.
    View in: PubMed
    Score: 0.007
  82. Dialing resistance up a Notch. Leuk Lymphoma. 2009 Feb; 50(2):158-9.
    View in: PubMed
    Score: 0.006
  83. Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1). Br J Haematol. 2009 Mar; 144(6):856-64.
    View in: PubMed
    Score: 0.006
  84. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett. 2009 Jul 18; 280(1):1-14.
    View in: PubMed
    Score: 0.006
  85. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009 Jan 01; 113(1):149-53.
    View in: PubMed
    Score: 0.006
  86. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2008 Sep 01; 112(5):1971-80.
    View in: PubMed
    Score: 0.006
  87. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol. 2009 Mar; 63(4):587-97.
    View in: PubMed
    Score: 0.006
  88. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008 Mar 01; 26(7):1098-105.
    View in: PubMed
    Score: 0.006
  89. RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol. 2008 Mar; 140(6):682-391.
    View in: PubMed
    Score: 0.006
  90. Questions about gemcitabine dose rate: answered or unanswered? J Clin Oncol. 2007 Dec 20; 25(36):5691-4.
    View in: PubMed
    Score: 0.006
  91. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Semin Oncol. 2007 Dec; 34(6 Suppl 5):S8-12.
    View in: PubMed
    Score: 0.006
  92. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 2007 Oct 15; 67(20):9913-20.
    View in: PubMed
    Score: 0.006
  93. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007 Sep 15; 110(6):1762-9.
    View in: PubMed
    Score: 0.006
  94. p53 as a predictor for chemotherapy response in CLL cells. Leuk Lymphoma. 2007 Feb; 48(2):219-20.
    View in: PubMed
    Score: 0.006
  95. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs. 2006 Dec; 15(12):1601-13.
    View in: PubMed
    Score: 0.006
  96. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood. 2007 Mar 15; 109(6):2557-64.
    View in: PubMed
    Score: 0.006
  97. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol. 2006 Nov; 18(6):584-90.
    View in: PubMed
    Score: 0.005
  98. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res. 2006 Jul 01; 12(13):4011-7.
    View in: PubMed
    Score: 0.005
  99. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006 Oct 01; 108(7):2392-8.
    View in: PubMed
    Score: 0.005
  100. Nelarabine. Nat Rev Drug Discov. 2006 Jan; 5(1):17-8.
    View in: PubMed
    Score: 0.005
  101. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res. 2005 Sep 15; 11(18):6745-52.
    View in: PubMed
    Score: 0.005
  102. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005 Dec 15; 106(13):4253-60.
    View in: PubMed
    Score: 0.005
  103. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005 Jun 01; 105(11):4455-62.
    View in: PubMed
    Score: 0.005
  104. The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer J. 2024 10 23; 14(1):168.
    View in: PubMed
    Score: 0.005
  105. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):361-368.
    View in: PubMed
    Score: 0.005
  106. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1417-23.
    View in: PubMed
    Score: 0.005
  107. In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol. 2004 Aug; 54(2):113-21.
    View in: PubMed
    Score: 0.005
  108. A structured curriculum supporting biomedical trainees' transition into independent academic positions and early career success. BMC Med Educ. 2024 Apr 08; 24(1):379.
    View in: PubMed
    Score: 0.005
  109. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003 Dec 15; 9(17):6335-42.
    View in: PubMed
    Score: 0.004
  110. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83.
    View in: PubMed
    Score: 0.004
  111. RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res. 2003 Nov 15; 63(22):7968-74.
    View in: PubMed
    Score: 0.004
  112. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2023 11 14; 7(21):6685-6701.
    View in: PubMed
    Score: 0.004
  113. A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics. Cancer. 2024 03 01; 130(5):727-739.
    View in: PubMed
    Score: 0.004
  114. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003 Sep 01; 102(5):1842-8.
    View in: PubMed
    Score: 0.004
  115. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 02 15; 129(4):580-589.
    View in: PubMed
    Score: 0.004
  116. Concurrent isolation of ribosomal, messenger, and low molecular weight RNA. Biotechniques. 2002 Nov; 33(5):1122-4.
    View in: PubMed
    Score: 0.004
  117. Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Antiviral Res. 2022 10; 206:105403.
    View in: PubMed
    Score: 0.004
  118. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol. 2002 Aug; 29(4 Suppl 13):4-11.
    View in: PubMed
    Score: 0.004
  119. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002 Jun 01; 62(11):3100-5.
    View in: PubMed
    Score: 0.004
  120. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2022 07; 63(7):1566-1579.
    View in: PubMed
    Score: 0.004
  121. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002 Feb 01; 20(3):665-73.
    View in: PubMed
    Score: 0.004
  122. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002; 41(2):93-103.
    View in: PubMed
    Score: 0.004
  123. Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res. 2022 02; 20(2):280-292.
    View in: PubMed
    Score: 0.004
  124. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
    View in: PubMed
    Score: 0.004
  125. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res. 2001 Jul 15; 61(14):5474-9.
    View in: PubMed
    Score: 0.004
  126. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
    View in: PubMed
    Score: 0.004
  127. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. J Hematol Oncol. 2021 04 26; 14(1):70.
    View in: PubMed
    Score: 0.004
  128. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001 Apr 15; 19(8):2142-52.
    View in: PubMed
    Score: 0.004
  129. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif. 2001; 19:21-45.
    View in: PubMed
    Score: 0.004
  130. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl. 2000 Aug 18; 745(2):421-30.
    View in: PubMed
    Score: 0.004
  131. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000 Mar; 18(5):995-1003.
    View in: PubMed
    Score: 0.003
  132. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 1999 Oct 01; 59(19):4937-43.
    View in: PubMed
    Score: 0.003
  133. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res. 2019 12; 7(12):2036-2051.
    View in: PubMed
    Score: 0.003
  134. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med. 2019 08 22; 381(8):789.
    View in: PubMed
    Score: 0.003
  135. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
    View in: PubMed
    Score: 0.003
  136. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res. 2019 07 01; 79(13):3251-3267.
    View in: PubMed
    Score: 0.003
  137. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998 Nov; 16(11):3607-15.
    View in: PubMed
    Score: 0.003
  138. Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents. J Med Chem. 2018 10 25; 61(20):9132-9145.
    View in: PubMed
    Score: 0.003
  139. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics. 2018 09 01; 19(14):1101-1110.
    View in: PubMed
    Score: 0.003
  140. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
    View in: PubMed
    Score: 0.003
  141. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 1998 Jul; 16(7):2321-31.
    View in: PubMed
    Score: 0.003
  142. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin Cancer Res. 1998 Jul; 4(7):1719-26.
    View in: PubMed
    Score: 0.003
  143. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer. 2018 05; 118(11):1425-1433.
    View in: PubMed
    Score: 0.003
  144. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells. Clin Cancer Res. 1997 Nov; 3(11):2107-13.
    View in: PubMed
    Score: 0.003
  145. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep; 3(9):1539-45.
    View in: PubMed
    Score: 0.003
  146. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res. 1997 Aug; 3(8):1347-55.
    View in: PubMed
    Score: 0.003
  147. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
    View in: PubMed
    Score: 0.003
  148. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
    View in: PubMed
    Score: 0.003
  149. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.
    View in: PubMed
    Score: 0.003
  150. Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells. Eur J Med Chem. 2017 Jun 16; 133:197-207.
    View in: PubMed
    Score: 0.003
  151. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985.
    View in: PubMed
    Score: 0.003
  152. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017 09; 58(9):1-17.
    View in: PubMed
    Score: 0.003
  153. Pharmacology of purine nucleoside analogues. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S67-74.
    View in: PubMed
    Score: 0.003
  154. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996 Oct; 23(5 Suppl 10):3-15.
    View in: PubMed
    Score: 0.003
  155. Prevention and Treatment of Cancer: Hypes and Hopes 6th International Translational Cancer Research Conference. Anticancer Res. 2016 09; 36(9):4971-5.
    View in: PubMed
    Score: 0.003
  156. Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells. Eur J Med Chem. 2016 Nov 10; 123:317-331.
    View in: PubMed
    Score: 0.003
  157. Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki. 1996 May; 37(5):369-79.
    View in: PubMed
    Score: 0.003
  158. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996 Apr; 2(4):653-8.
    View in: PubMed
    Score: 0.003
  159. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 01; 87(1):256-64.
    View in: PubMed
    Score: 0.003
  160. Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec; 6 Suppl 6:7-13.
    View in: PubMed
    Score: 0.003
  161. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. PLoS One. 2015; 10(8):e0135962.
    View in: PubMed
    Score: 0.003
  162. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug; 22(4 Suppl 11):3-10.
    View in: PubMed
    Score: 0.003
  163. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995 Aug; 22(4 Suppl 11):61-7.
    View in: PubMed
    Score: 0.003
  164. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. Int J Oncol. 2015 Aug; 47(2):782-90.
    View in: PubMed
    Score: 0.002
  165. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res. 2015 Apr 01; 21(7):1537-42.
    View in: PubMed
    Score: 0.002
  166. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995 Feb; 1(2):169-78.
    View in: PubMed
    Score: 0.002
  167. Multi-targeted approach to cancer treatment: an international translational cancer research symposium. Anticancer Res. 2014 Nov; 34(11):6791-5.
    View in: PubMed
    Score: 0.002
  168. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8.
    View in: PubMed
    Score: 0.002
  169. Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes. J Med Chem. 2014 Jun 12; 57(11):4498-510.
    View in: PubMed
    Score: 0.002
  170. Evolution of the arabinosides and the pharmacology of fludarabine. Drugs. 1994; 47 Suppl 6:30-8.
    View in: PubMed
    Score: 0.002
  171. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994; 14 Suppl 2:11-6.
    View in: PubMed
    Score: 0.002
  172. Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol. 1994; 370:119-24.
    View in: PubMed
    Score: 0.002
  173. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 1994; 14 Suppl 2:3-9.
    View in: PubMed
    Score: 0.002
  174. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994; 34(1):30-6.
    View in: PubMed
    Score: 0.002
  175. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8.
    View in: PubMed
    Score: 0.002
  176. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):13-20.
    View in: PubMed
    Score: 0.002
  177. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66.
    View in: PubMed
    Score: 0.002
  178. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncol. 2013 Aug; 9(8):1073-82.
    View in: PubMed
    Score: 0.002
  179. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma. 1993 May; 10(1-2):49-56.
    View in: PubMed
    Score: 0.002
  180. Cellular pharmacodynamics of anticancer drugs. Semin Oncol. 1993 Feb; 20(1):50-63.
    View in: PubMed
    Score: 0.002
  181. Fludarabine for treatment of adult acute myelogenous leukemia. Leuk Lymphoma. 1993; 11 Suppl 2:7-13.
    View in: PubMed
    Score: 0.002
  182. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993 Jan; 11(1):116-24.
    View in: PubMed
    Score: 0.002
  183. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993; 10 Suppl:109-14.
    View in: PubMed
    Score: 0.002
  184. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
    View in: PubMed
    Score: 0.002
  185. Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. PLoS One. 2012; 7(7):e41455.
    View in: PubMed
    Score: 0.002
  186. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
    View in: PubMed
    Score: 0.002
  187. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992 Feb 15; 52(4):897-903.
    View in: PubMed
    Score: 0.002
  188. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol. 1992; 31(1):11-7.
    View in: PubMed
    Score: 0.002
  189. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9.
    View in: PubMed
    Score: 0.002
  190. Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs. J Am Chem Soc. 2011 Dec 07; 133(48):19278-81.
    View in: PubMed
    Score: 0.002
  191. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8.
    View in: PubMed
    Score: 0.002
  192. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct; 339(1):9-23.
    View in: PubMed
    Score: 0.002
  193. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics. 2011 Mar; 12(3):327-39.
    View in: PubMed
    Score: 0.002
  194. Defective molecular timer in the absence of nucleotides leads to inefficient caspase activation. PLoS One. 2011 Jan 27; 6(1):e16379.
    View in: PubMed
    Score: 0.002
  195. Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol. 1991; 309A:125-30.
    View in: PubMed
    Score: 0.002
  196. Metabolism and action of fludarabine phosphate. Semin Oncol. 1990 Oct; 17(5 Suppl 8):3-17.
    View in: PubMed
    Score: 0.002
  197. Forodesine: review of preclinical and clinical data. Future Oncol. 2010 Aug; 6(8):1211-7.
    View in: PubMed
    Score: 0.002
  198. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010 Aug 15; 70(16):6587-97.
    View in: PubMed
    Score: 0.002
  199. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990 Jun 15; 50(12):3675-80.
    View in: PubMed
    Score: 0.002
  200. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia. 2010 May; 12(5):366-75.
    View in: PubMed
    Score: 0.002
  201. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 2010 Aug 12; 116(6):886-92.
    View in: PubMed
    Score: 0.002
  202. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.
    View in: PubMed
    Score: 0.002
  203. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood. 1989 Nov 01; 74(6):2070-5.
    View in: PubMed
    Score: 0.002
  204. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol. 1989 Oct 15; 38(20):3551-8.
    View in: PubMed
    Score: 0.002
  205. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50.
    View in: PubMed
    Score: 0.002
  206. Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. J Biol Chem. 2009 Sep 25; 284(39):26816-30.
    View in: PubMed
    Score: 0.002
  207. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37.
    View in: PubMed
    Score: 0.002
  208. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia. 2009 Aug; 23(8):1410-6.
    View in: PubMed
    Score: 0.002
  209. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res. 2009 Mar 01; 15(5):1762-9.
    View in: PubMed
    Score: 0.002
  210. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 07; 113(19):4637-45.
    View in: PubMed
    Score: 0.002
  211. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008 Dec 01; 113(11):3181-5.
    View in: PubMed
    Score: 0.002
  212. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol. 2008 Aug; 142(4):551-61.
    View in: PubMed
    Score: 0.002
  213. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol. 2008 Mar; 15(2):101-7.
    View in: PubMed
    Score: 0.002
  214. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988 Jan 15; 48(2):329-34.
    View in: PubMed
    Score: 0.001
  215. Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct; 48(10):1922-30.
    View in: PubMed
    Score: 0.001
  216. miRNAs and their potential for use against cancer and other diseases. Future Oncol. 2007 Oct; 3(5):521-37.
    View in: PubMed
    Score: 0.001
  217. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007 Dec; 323(3):935-45.
    View in: PubMed
    Score: 0.001
  218. Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport. Leuk Lymphoma. 2007 Sep; 48(9):1816-27.
    View in: PubMed
    Score: 0.001
  219. Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr. 1987 Jan 23; 413:293-9.
    View in: PubMed
    Score: 0.001
  220. Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Mol Cancer Ther. 2006 Dec; 5(12):3062-70.
    View in: PubMed
    Score: 0.001
  221. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006 Nov 15; 66(22):10959-66.
    View in: PubMed
    Score: 0.001
  222. Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome. Cell. 2006 Jun 30; 125(7):1333-46.
    View in: PubMed
    Score: 0.001
  223. All pathways to cancer apoptosis meeting in Thiruvananthapuram (India). Cell Death Differ. 2006 Dec; 13(12):2163-4.
    View in: PubMed
    Score: 0.001
  224. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24.
    View in: PubMed
    Score: 0.001
  225. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6.
    View in: PubMed
    Score: 0.001
  226. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005 Oct 01; 106(7):2513-9.
    View in: PubMed
    Score: 0.001
  227. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005 May 20; 23(15):3396-403.
    View in: PubMed
    Score: 0.001
  228. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer. 2005 May 15; 103(10):1985-95.
    View in: PubMed
    Score: 0.001
  229. 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther. 2005 Apr; 4(4):569-77.
    View in: PubMed
    Score: 0.001
  230. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22.
    View in: PubMed
    Score: 0.001
  231. 8-amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol Cancer Ther. 2004 Nov; 3(11):1411-20.
    View in: PubMed
    Score: 0.001
  232. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7.
    View in: PubMed
    Score: 0.001
  233. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9.
    View in: PubMed
    Score: 0.001
  234. The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G. Biochem Pharmacol. 2003 Sep 01; 66(5):733-7.
    View in: PubMed
    Score: 0.001
  235. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86.
    View in: PubMed
    Score: 0.001
  236. Paecilomyces peritonitis: case report and review of the literature. Clin Nephrol. 2003 Apr; 59(4):305-10.
    View in: PubMed
    Score: 0.001
  237. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73.
    View in: PubMed
    Score: 0.001
  238. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene. 2003 Jan 09; 22(1):131-46.
    View in: PubMed
    Score: 0.001
  239. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther. 2002 Nov; 1(13):1221-7.
    View in: PubMed
    Score: 0.001
  240. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002 Oct 15; 20(20):4217-24.
    View in: PubMed
    Score: 0.001
  241. Prolonged stability and sustained prodrug cell killing activity using receptor-mediated delivery of malarial circumsporozoite-cytosine deaminase fusion protein into liver cancer cells. Mol Cancer Ther. 2002 May; 1(7):461-7.
    View in: PubMed
    Score: 0.001
  242. Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol. 2002 Jan; 61(1):222-9.
    View in: PubMed
    Score: 0.001
  243. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002; 20:37-58.
    View in: PubMed
    Score: 0.001
  244. Gemcitabine in hematologic malignancies. Curr Opin Oncol. 2001 Nov; 13(6):514-21.
    View in: PubMed
    Score: 0.001
  245. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001 Aug 01; 19(15):3483-9.
    View in: PubMed
    Score: 0.001
  246. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999 Dec; 36(1-2):57-65.
    View in: PubMed
    Score: 0.001
  247. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999 Jul; 106(1):78-85.
    View in: PubMed
    Score: 0.001
  248. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 1999 Jan 01; 85(1):58-64.
    View in: PubMed
    Score: 0.001
  249. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S83-91.
    View in: PubMed
    Score: 0.001
  250. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9.
    View in: PubMed
    Score: 0.001
  251. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother Pharmacol. 1996; 38(3):261-8.
    View in: PubMed
    Score: 0.001
  252. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan; 31(1):28-39.
    View in: PubMed
    Score: 0.001
  253. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol. 1994; 5 Suppl 2:79-83.
    View in: PubMed
    Score: 0.001
  254. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):2-12.
    View in: PubMed
    Score: 0.001
  255. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 1993 Oct 01; 72(7):2155-60.
    View in: PubMed
    Score: 0.001
  256. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993 Mar; 9(4-5):343-50.
    View in: PubMed
    Score: 0.001
  257. Raising plasma phosphorus levels by phosphorus-enriched, bicarbonate-containing dialysate in hemodialysis patients. Artif Organs. 1992 Aug; 16(4):414-6.
    View in: PubMed
    Score: 0.001
  258. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol. 1992; 31(3):193-9.
    View in: PubMed
    Score: 0.000
  259. Peritoneal dialysis using bicarbonate-containing solution sterilized by ultrafiltration. Int J Artif Organs. 1991 Aug; 14(8):463-5.
    View in: PubMed
    Score: 0.000
  260. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia. 1987 Sep; 1(9):638-43.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.